Semaglutide
Also known as: GLP-1 receptor agonist, Ozempic, Wegovy, Rybelsus
Classification
Peptide
Regulatory Status
FDA-approved prescription product (Ozempic/Wegovy/Rybelsus product-specific labels)
Sources
3
Review
n/a
Overview
Semaglutide is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite; labeled products are used for type 2 diabetes and chronic weight management contexts per product-specific labeling.
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
Pathways
Benefits
DailyMed identifies Ozempic (semaglutide) injection for glycemic control in adults with type 2 diabetes and for certain cardiovascular-risk contexts described in labeling. Educational reference only.
DailyMed identifies Wegovy (semaglutide) with diet and physical activity for chronic weight-management and cardiovascular-risk contexts described in the product label. Educational reference only.
Interactions & cautions
Drug interactions
insulin or insulin secretagogues (e.g., sulfonylureas) — Increased hypoglycemia risk. (high)
other GLP-1 receptor agonists — Redundant therapy and additive GI adverse effects. (review)
These are observational flags for review, not individualized instructions.
Sources
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6da837c-0da0-41d6-973c-5559bf764367 (opens in a new tab)
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b (opens in a new tab)
- https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss (opens in a new tab)
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
None recorded in our sources.
Effects measured:
Human trials: none found.
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw